Press Releases

A widely accessible drug commonly used to control blood glucose levels in diabetic patients has the potential to strengthen the effects of immunotherapy and improve recurrence-free survival in people with lung cancer who are overweight or obese, according to work newly published in the Journal of the National Cancer Institute and led by Roswell Park's Sai Yendamuri, MD, MBA, FACS.

Roswell Park, in partnership with the University at Buffalo School of Nursing, has received a five-year, $2.11 million Institutional Clinical Scientist Awards (K12) grant from the National Cancer Institute to establish a training program for nurse-scientists focused around clinical translational research.

Roswell Park experts representing various specialties will highlight innovative research and advancements in hematology and hematologic cancers at the 66th annual meeting of the American Society of Hematology (ASH), to be held December 7-10 in San Diego.

A new treatment approach developed at Roswell Park has shown promising results in a phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.

Kimberly Sweeney, MBA, RN, was awarded the distinguished Trooper Stetson Award by the New York State Troopers Police Benevolent Association (PBA), and Ashley Snowden, received the Meritorious Service Award from Buffalo firefighters.

Roswell Park Comprehensive Cancer Center has applied to the American Nurses Credentialing Center (ANCC) for the prestigious designation of Magnet. Magnet designation recognizes excellence in nursing services.

A new study led by Andrei Gudkov, PhD, DSci, at Roswell Park supports a new understanding of what might be driving one mammal's propensity for avoiding cancer — its noteworthy evolutionary stability.

Updated results from a phase 3 clinical trial co-developed by Roswell Park's Dr. Kara Kelly are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated in newly diagnosed adolescents and adults. Details appear in a study published today in The New England Journal of Medicine.